Table 1.

Demographic and clinical characteristics and baseline measurements at pretreatment assessment

	Placebo group	Cortisol group	Significance, P
Females/males	9/11	9/11	1.0
Age	40.2 (2.6)	42.8 (2.4)	0.461
BMI	26.4 (1.1)	25.6 (0.8)	0.558
Severity primary diagnosis	5.4 (0.2)	5.4 (0.2)	0.874
BDI total score	5.7 (1.2)	4.0 (1.0)	0.280
ASI total score	17.9 (1.8)	16.2 (1.8)	0.498
STAI trait total score	39.2 (1.8)	36.1 (1.4)	0.185
ITQ	5.3 (1.2)	4.2 (1.2)	0.524
AQ	58.9 (4.4)	58.4 (4.1)	0.927
ATHQ	41.5 (2.7)	39.3 (2.0)	0.517
DES	18.3 (1.0)	18.6 (0.9)	0.847
AES	20.1 (1.3)	20.0 (1.3)	0.962
Treatment credibility	23.6 (0.8)	22.8 (0.6)	0.462
SUD	48.8 (5.3)	49.4 (4.8)	0.940
BAT score	4.3 (0.4)	4.1 (0.4)	0.792

Data presented as mean (SEM). AES, anxiety expectancy scale; AQ, acrophobia questionnaire; ASI, anxiety sensitivity index; ATHQ, attitude toward heights questionnaire; BAT, behavioral avoidance test; BDI, Beck depression inventory; BMI, body mass index; DES, danger expectancy scale; ITQ, immersive tendencies questionnaire; STAI, state-trait anxiety inventory; SUD, subjective units of discomfort.